Based on the Praxis Precision Medicines Inc stock forecast from 8 analysts, the average analyst target price for Praxis Precision Medicines Inc is USD 105.38 over the next 12 months. Praxis Precision Medicines Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Praxis Precision Medicines Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Praxis Precision Medicines Inc’s stock price was USD 30.85. Praxis Precision Medicines Inc’s stock price has changed by -16.87% over the past week, -19.87% over the past month and -41.47% over the last year.
No recent analyst target price found for Praxis Precision Medicines Inc
No recent average analyst rating found for Praxis Precision Medicines Inc
Company Overview Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. Read Less
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-t...Read More
Frequently Asked Questions About Praxis Precision Medicines Inc (PRAX) Stock
Based on ratings from 8 analysts Praxis Precision Medicines Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on PRAX's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for PRAX is USD 105.38 over the next 12 months. The maximum analyst target price is USD 150 while the minimum anlayst target price is USD 73.
Unfortunately we do not have enough data on PRAX's stock to indicate if its overvalued.
The last closing price of PRAX's stock was USD 30.85.
The most recent market capitalization for PRAX is USD 0.76B.
Based on targets from 8 analysts, the average taret price for PRAX is projected at USD 105.38 over the next 12 months.
This means that PRAX's stock price may go up by +241.57% over the next 12 months.
We can't find any ETFs which contains Praxis Precision Medicines Inc's stock.
As per our most recent records Praxis Precision Medicines Inc has 116 Employees.
Praxis Precision Medicines Inc's registered address is 99 High Street, Boston, MA, United States, 02110.
You can get more information about it from Praxis Precision Medicines Inc's website at https://praxismedicines.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Praxis Precision Medicines Inc (PRAX) Stock
Based on ratings from 8 analysts Praxis Precision Medicines Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on PRAX's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for PRAX is USD 105.38 over the next 12 months. The maximum analyst target price is USD 150 while the minimum anlayst target price is USD 73.
Unfortunately we do not have enough data on PRAX's stock to indicate if its overvalued.
The last closing price of PRAX's stock was USD 30.85.
The most recent market capitalization for PRAX is USD 0.76B.
Based on targets from 8 analysts, the average taret price for PRAX is projected at USD 105.38 over the next 12 months.
This means that PRAX's stock price may go up by +241.57% over the next 12 months.
We can't find any ETFs which contains Praxis Precision Medicines Inc's stock.
As per our most recent records Praxis Precision Medicines Inc has 116 Employees.
Praxis Precision Medicines Inc's registered address is 99 High Street, Boston, MA, United States, 02110.
You can get more information about it from Praxis Precision Medicines Inc's website at https://praxismedicines.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRAX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
